

LA JOLLA PHARMACEUTICAL CO

Form 8-K/A

August 01, 2003

**Table of Contents**

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

---

**FORM 8-K/A**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): June 16, 2003

**La Jolla Pharmaceutical Company**

(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation)	0-24274 (Commission File Number)	33-0361285 (IRS Employer Identification No.)
---	--	--

6455 Nancy Ridge Drive, San Diego, California (Address of Principal Executive Offices)	92121 (Zip Code)
---	---------------------

Registrant's telephone number, including area code: (858) 452-6600

---

**TABLE OF CONTENTS**

ITEM 5. OTHER EVENTS

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND  
EXHIBITS.

SIGNATURES

EXHIBIT 99.1

---

**Table of Contents**

*Explanatory Note:* This Form 8-K/A and the related Press Release filed herewith as Exhibit 99.1 is filed to correct information in the third sentence of the fifth paragraph of the Press Release as previously filed.

**ITEM 5. OTHER EVENTS**

On June 16, 2003, the Company issued a press release announcing, among other matters, the health-related quality of life results from the Riquent Phase 3 trial. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.**

The following exhibits are filed with this report on Form 8-K:

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
99.1	Press Release

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**LA JOLLA PHARMACEUTICAL COMPANY**

Date: August 1, 2003

By: /s/ Steven B. Engle

\_\_\_\_\_  
Steven B. Engle  
Chairman and Chief Executive Officer